SpringWorks Therapeutics Inc (NAS:SWTX)
$ 41.48 -0.25 (-0.6%) Market Cap: 3.09 Bil Enterprise Value: 2.72 Bil PE Ratio: 0 PB Ratio: 5.79 GF Score: 38/100

SpringWorks Therapeutics to Discuss the Reneu Trial Data and Program Update Call Transcript

Feb 25, 2021 / 01:30PM GMT
Release Date Price: $89 (-4.90%)
Operator

Welcome to the SpringWorks Therapeutics First Quarter 2021 ReNeu Trial Update Conference Call. My name is John. (Operator Instructions)

And now I'll turn the call over to Kim Diamond, Vice President of Communications and Investor Relations at SpringWorks Therapeutics. Kim, you may begin.

Kim Diamond
SpringWorks Therapeutics Inc. - VP, Communications & IR

Thank you, John. Good morning and thank you for joining us today for the Phase 2b ReNeu trial update call. Slides to accompany this conference call are posted in the Investors and Media section of our website at www.springworkstx.com and an audio webcast with the corresponding slides is also available on the website.

In addition, we will plan to update our investor presentation following this morning's call. Leading the call today will be SpringWorks' CEO, Saqib Islam. Saqib is joined by our Chief Development Officer, Dr. Mary Smith and our Chief Operating Officer, Dr. Badreddin Edris. Following our prepared remarks,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot